Address
830 Winter Street
Waltham, MA 02451-1477
United States of America (the)
Phone
781 895 0600
Website
Sector
Healthcare
Industry
Biotechnology
Employees
277
First IPO Date
November 17, 1989
| Name | Title | Pay | Year Born |
| Mark Joseph Enyedy | President, Chief Executive Officer & Director | 1.28M | 1964 |
| Michael J. Vasconcelles | Chief Medical Officer | 304,620 | 1963 |
| Lauren A. White | Senior Vice President & Chief Financial Officer | 537,532 | 1979 |
| Theresa G. Wingrove | Senior Vice President of Regulatory Affairs & Quality | 548,205 | 1958 |
| Stacy A. Coen | Senior Vice President & Chief Business Officer | 584,042 | 1971 |
| Anabel Chan | Head of Investor Relations | 0 | N/A |
| Daniel S. Char | Senior Vice President, Chief Legal Officer & Secretary | 0 | 1962 |
| Audrey Bergan | Senior Vice President & Chief HR Officer | 0 | N/A |
| Courtney O'Konek | Senior Director of Corporation Communications & Investor Relations | 0 | N/A |
| Isabel Kalofonos | Senior Vice President & Chief Commercial Officer | 0 | N/A |
ImmunoGen, Inc. is a clinical-stage biotechnology enterprise that specializes in the creation of antibody-drug conjugate (ADC) therapies for cancer treatment. A prominent drug in their pipeline is mirvetuximab soravtansine, an ADC designed to target folate-receptor alpha (FRa), which is currently undergoing Phase III clinical trials for patients with platinum-resistant ovarian cancer. Another significant candidate, Pivekimab sunirine, a CD123-targeting ADC, is progressing through Phase II studies for acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Beyond its clinical efforts, the company's preclinical portfolio includes IMGC936, an ADC being co-developed with MacroGenics, Inc., and IMGN151, another anti-FRa therapeutic. ImmunoGen maintains strategic collaborations with a range of key industry players, such as Roche, Amgen/Oxford BioTherapeutics, Bayer HealthCare AG, Eli Lilly and Company, Novartis Institutes for BioMedical Research, Inc., CytomX Therapeutics, Inc., Fusion Pharmaceuticals Inc., Debiopharm International SA, and MacroGenics, Inc. Founded in 1980, ImmunoGen, Inc. is headquartered in Waltham, Massachusetts.